User:Mr. Ibrahem/Abemaciclib
 | |
| Clinical data | |
|---|---|
| Pronunciation | /ʌˌbɛməˈsaɪklɪb/ u-BEM-ə-SY-klib |
| Trade names | Verzenio, Verzenios, Ramiven, Zenlistik, others |
| Other names | LY2835219 |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | By mouth (tablets) |
| Drug class | CDK inhibitor[1] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 45% |
| Protein binding | 96.3% |
| Elimination half-life | 18.3 hrs |
| Excretion | 81% via feces, 3% via urine |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C27H32F2N8 |
| Molar mass | 506.606 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Abemaciclib, sold under the brand names Verzenio among others, is a medication used to treat breast cancer.[1] Specifically it is used for advanced cases that are HR positive but HER2 negative.[1] It is taken by mouth.[3]
Common side effects include diarrhea, low white blood cells, nausea, infections, tiredness, hair loss, and low platelets.[2] Other side effects may include pneumonitis, liver problems, and blood clots.[2] Use in pregnancy may harm the baby.[2] It is a CDK inhibitor which blocks the activity of CDK4 and CDK6.[1]
Abemaciclib was approved for medical use in the United States in 2017 and Europe in 2018.[2][1] In the United Kingdom 4 weeks costs the NHS about £2,950 as of 2021.[3] In the United States this amount costs about 13,700 USD.[4]
References
- ^ a b c d e f "Verzenios". Archived from the original on 3 June 2021. Retrieved 13 January 2022.
- ^ a b c d e "DailyMed - VERZENIO- abemaciclib tablet". dailymed.nlm.nih.gov. Archived from the original on 13 May 2021. Retrieved 13 January 2022.
- ^ a b BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1010. ISBN 978-0857114105.
- ^ "Verzenio Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 16 January 2021. Retrieved 13 January 2022.